BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14666705)

  • 1. Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis.
    Freier K; Bosch FX; Flechtenmacher C; Devens F; Benner A; Lichter P; Joos S; Hofele C
    Anticancer Res; 2003; 23(5A):3971-7. PubMed ID: 14666705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck.
    Do NY; Lim SC; Im TS
    Oncol Rep; 2004 Aug; 12(2):229-37. PubMed ID: 15254682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma.
    Ch'ng S; Low I; Ng D; Brasch H; Sullivan M; Davis P; Tan ST
    Hum Pathol; 2008 Mar; 39(3):344-9. PubMed ID: 18045646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma.
    Freier K; Joos S; Flechtenmacher C; Devens F; Benner A; Bosch FX; Lichter P; Hofele C
    Cancer Res; 2003 Mar; 63(6):1179-82. PubMed ID: 12649172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression.
    O-Charoenrat P; Rhys-Evans P; Eccles S
    Anticancer Res; 2001; 21(3B):1953-63. PubMed ID: 11497283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Pim-1 in head and neck squamous cell carcinomas.
    Beier UH; Weise JB; Laudien M; Sauerwein H; Görögh T
    Int J Oncol; 2007 Jun; 30(6):1381-7. PubMed ID: 17487358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of signal transducers and activators of transcription 3 and overexpression of its target gene CyclinD1 in laryngeal carcinomas.
    Liu B; Ren Z; Shi Y; Guan C; Pan Z; Zong Z
    Laryngoscope; 2008 Nov; 118(11):1976-80. PubMed ID: 18758380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck.
    Yu Z; Weinberger PM; Provost E; Haffty BG; Sasaki C; Joe J; Camp RL; Rimm DL; Psyrri A
    Clin Cancer Res; 2005 Apr; 11(7):2471-7. PubMed ID: 15814622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas.
    Fischer C; Zlobec I; Stöckli E; Probst S; Storck C; Tornillo L; Lugli A; Wolfensberger M; Terracciano L
    Hum Pathol; 2008 Oct; 39(10):1527-34. PubMed ID: 18620726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.
    Silva SD; Cunha IW; Younes RN; Soares FA; Kowalski LP; Graner E
    Oral Dis; 2010 Nov; 16(8):774-80. PubMed ID: 20604875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of cell cycle regulatory proteins correlates with advanced tumor stage in head and neck squamous cell carcinomas.
    Nguyen DC; Parsa B; Close A; Magnusson B; Crowe DL; Sinha UK
    Int J Oncol; 2003 Jun; 22(6):1285-90. PubMed ID: 12738995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study.
    Silva SD; Agostini M; Nishimoto IN; Coletta RD; Alves FA; Lopes MA; Kowalski LP; Graner E
    Oral Oncol; 2004 Aug; 40(7):688-96. PubMed ID: 15172638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of tissue array technology in head and neck squamous cell carcinoma.
    Chen B; van den Brekel MW; Buschers W; Balm AJ; van Velthuysen ML
    Head Neck; 2003 Nov; 25(11):922-30. PubMed ID: 14603452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas.
    Cavalot A; Martone T; Roggero N; Brondino G; Pagano M; Cortesina G
    Head Neck; 2007 Jul; 29(7):655-64. PubMed ID: 17315173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.
    López-Malpartida AV; Ludeña MD; Varela G; García Pichel J
    Lung Cancer; 2009 Jul; 65(1):25-33. PubMed ID: 19046792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of risk factors in the prediction of distant metastases of head and neck squamous cell carcinomas].
    Li XM; Di B; Shang YD; Zhou YQ; Ma HM; Cheng JM
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Mar; 39(3):171-5. PubMed ID: 15283298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
    Sinha UK; Mazhar K; Chinn SB; Dhillon VK; Liu L; Masood R; Rice DH; Gill PS
    Arch Otolaryngol Head Neck Surg; 2006 Oct; 132(10):1053-9. PubMed ID: 17043250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
    Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
    J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.